Certara, Inc. (CERT)

NASDAQ: CERT · Real-Time Price · USD
11.37
-0.23 (-1.98%)
At close: Dec 11, 2024, 4:00 PM
10.80
-0.57 (-5.01%)
Pre-market: Dec 12, 2024, 7:38 AM EST
-1.98%
Market Cap 1.83B
Revenue (ttm) 372.80M
Net Income (ttm) -31.08M
Shares Out 160.97M
EPS (ttm) -0.20
PE Ratio n/a
Forward PE 22.90
Dividend n/a
Ex-Dividend Date n/a
Volume 1,171,580
Open 11.62
Previous Close 11.60
Day's Range 11.05 - 11.68
52-Week Range 9.41 - 19.87
Beta 1.53
Analysts Buy
Price Target 15.92 (+40.02%)
Earnings Date Nov 6, 2024

About CERT

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new dr... [Read more]

Sector Healthcare
IPO Date Dec 11, 2020
Employees 1,391
Stock Exchange NASDAQ
Ticker Symbol CERT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for CERT stock is "Buy." The 12-month stock price forecast is $15.92, which is an increase of 40.02% from the latest price.

Price Target
$15.92
(40.02% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Certara Showcases 2024 Research Wins With Over 100 Papers Published

The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researc...

9 days ago - GlobeNewsWire

Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript

Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript

5 weeks ago - Seeking Alpha

Certara Reports Third Quarter 2024 Financial Results

RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal ye...

5 weeks ago - GlobeNewsWire

Certara to Participate in the Stephens Annual Investment Conference

RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephen...

6 weeks ago - GlobeNewsWire

Certara Appoints John Reynders as New Independent Board Member

RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of ...

2 months ago - GlobeNewsWire

Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024

RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third qu...

2 months ago - GlobeNewsWire

Certara Completes Acquisition of Chemaxon

Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry.

2 months ago - GlobeNewsWire

Final Trade: Certara, Nextera Energy, Knight-Swift Transportation and Lululemon

The final trades of the day with the Fast Money traders.

Other symbols: KNXLULUNEE
2 months ago - CNBC Television

Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug

Certara shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001.

3 months ago - GlobeNewsWire

Certara to Participate in Upcoming Investor Conferences

RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the followi...

4 months ago - GlobeNewsWire

Certara Launches Phoenix™ Version 8.5 Drug Development Software

RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5.

4 months ago - GlobeNewsWire

Certara, Inc. (CERT) Q2 2024 Earnings Call Transcript

Certara, Inc. (NASDAQ:CERT) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive ...

4 months ago - Seeking Alpha

Certara Reports Second Quarter 2024 Financial Results

RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal y...

4 months ago - GlobeNewsWire

Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio

Combined organization brings broader predictive capabilities to drug discovery at scale Reiterates full year 2024 guidance RADNOR, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), ...

5 months ago - GlobeNewsWire

Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024

RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second q...

5 months ago - GlobeNewsWire

Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software

Certara today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers.

6 months ago - GlobeNewsWire

Certara to Participate in the Jefferies Global Healthcare Conference

RADNOR, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcar...

7 months ago - GlobeNewsWire

Certara Appoints New Chief Human Resources Officer & General Counsel

RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Co...

7 months ago - GlobeNewsWire

Certara, Inc. (CERT) Q1 2024 Earnings Call Transcript

Certara, Inc. (NASDAQ:CERT) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations William Feehery - Chief Executive Officer John Gallagher -...

7 months ago - Seeking Alpha

Certara Reports First Quarter 2024 Financial Results

PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2024.

7 months ago - GlobeNewsWire

Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform

Certara Cloud is a unifying platform that integrates Certara's scientific software. Clients use a single ID to access and manage their licensed software.

8 months ago - GlobeNewsWire

Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference

PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024...

8 months ago - GlobeNewsWire

Certara Inc. (CERT) Q4 2023 Earnings Call Transcript

Certara Inc. (CERT) Q4 2023 Earnings Call Transcript

10 months ago - Seeking Alpha

Certara Reports Fourth Quarter 2023 Financial Results

PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023.

10 months ago - GlobeNewsWire

Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference

PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and ful...

11 months ago - GlobeNewsWire